Chinese Journal of Dermatology ›› 2025, Vol. 58 ›› Issue (11): 1015-1019.doi: 10.35541/cjd.20250249
• Expert Commentary • Previous Articles Next Articles
Shao Shuai, Wang Gang
Received:2025-04-30
Revised:2025-06-10
Online:2025-11-15
Published:2025-11-03
Contact:
Wang Gang
E-mail:xjwgang@fmmu.edu.cn
Supported by:Shao Shuai, Wang Gang. Treatment and diagnosis of generalized pustular psoriasis: advances, challenges, and prospects[J]. Chinese Journal of Dermatology, 2025, 58(11): 1015-1019.doi:10.35541/cjd.20250249
| [1] | Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in Asia? A population⁃based study using claim data in China and a systematic review[J]. Dermatology, 2023,239(2):195⁃205. doi: 10.1159/000528850. |
| [2] | Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis[J]. Am J Hum Genet, 2011,89(3):432⁃437. doi: 10. 1016/j.ajhg.2011.07.022. |
| [3] | Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin⁃36⁃receptor antagonist deficiency and generalized pustular psoriasis[J]. N Engl J Med, 2011,365(7):620⁃628. doi: 10.1056/NEJ Moa1013068. |
| [4] | Elias M, Zhao S, Le HT, et al. IL⁃36 in chronic inflammation and fibrosis ⁃ bridging the gap?[J]. J Clin Invest, 2021,131(2):e144336. doi: 10.1172/JCI144336. |
| [5] | Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris[J]. J Invest Dermatol, 2015,135(12):2964⁃2970. doi: 10.1038/jid.2015.288. |
| [6] | Setta⁃Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll⁃like receptor 3 trafficking[J]. Am J Hum Genet, 2014,94(5):790⁃797. doi: 10.1016/j.ajhg.2014.04.005. |
| [7] | Haskamp S, Bruns H, Hahn M, et al. Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases[J]. Am J Hum Genet, 2020,107(3):527⁃538. doi: 10.1016/j.ajhg.2020.07.001. |
| [8] | Frey S, Sticht H, Wilsmann⁃Theis D, et al. Rare loss⁃of⁃function mutation in SERPINA3 in generalized pustular psoriasis[J]. J Invest Dermatol, 2020,140(7):1451⁃1455. doi: 10.1016/j.jid. 2019.11.024. |
| [9] | Kantaputra P, Chaowattanapanit S, Kiratikanon S, et al. SERPINA1, generalized pustular psoriasis, and adult⁃onset immunodeficiency[J]. J Dermatol, 2021,48(10):1597⁃1601. doi: 10.1111/1346⁃8138.16081. |
| [10] | Zhang Q, Shi P, Wang Z, et al. Identification of the BTN3A3 gene as a molecule implicated in generalized pustular psoriasis in a Chinese population[J]. J Invest Dermatol, 2023,143(8):1439⁃1448.e21. doi: 10.1016/j.jid.2023.01.023. |
| [11] | Yoshikawa T, Takeichi T, Nishida K, et al. MEFV variants are a predisposing factor for generalized pustular psoriasis[J]. J Am Acad Dermatol, 2024,90(4):852⁃854. doi: 10.1016/j.jaad. 2023.10.070. |
| [12] | Han JW, Wang Y, Alateng C, et al. Tumor necrosis factor⁃alpha induced protein 3 interacting protein 1 gene polymorphisms and pustular psoriasis in Chinese Han population[J]. Chin Med J (Engl), 2016,129(13):1519⁃1524. doi: 10.4103/0366⁃6999. 184470. |
| [13] | Johnston A, Xing X, Wolterink L, et al. IL⁃1 and IL⁃36 are dominant cytokines in generalized pustular psoriasis[J]. J Allergy Clin Immunol, 2017,140(1):109⁃120. doi: 10.1016/j.jaci.2016.08.056. |
| [14] | Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis[J]. N Engl J Med, 2021,385(26):2431⁃2440. doi: 10.1056/NEJMoa2111563. |
| [15] | Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo⁃controlled trial[J]. Lancet, 2023,402(10412):1541⁃1551. doi: 10.1016/S0140⁃6736(23)01378⁃8. |
| [16] | Gordon KB, Augustin M, Barker J, et al. Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: post hoc analysis of the EFFISAYIL 2 study[J]. J Am Acad Dermatol, 2025,92(6):1235⁃1242. doi: 10.1016/j.jaad. 2025.01.089. |
| [17] | 中国医师协会皮肤科医师分会儿童学组, 中华医学会皮肤性病学分会银屑病学组. 儿童脓疱型银屑病诊疗中国专家共识(2025版)[J]. 中华皮肤科杂志, 2025,58(4):297⁃306. doi: 10.35541/cjd.20240714. |
| [18] | Carrier Y, Ma HL, Ramon HE, et al. Inter⁃regulation of Th17 cytokines and the IL⁃36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis[J]. J Invest Dermatol, 2011,131(12):2428⁃2437. doi: 10.1038/jid.2011.234. |
| [19] | Ovesen SK, Schulze⁃Osthoff K, Iversen L, et al. IkBζ is a key regulator of tumour necrosis factor⁃a and interleukin⁃17A⁃mediated induction of interleukin⁃36g in human keratinocytes[J]. Acta Derm Venereol, 2021,101(2):adv00386. doi: 10.2340/00015555⁃3749. |
| [20] | Friedrich M, Tillack C, Wollenberg A, et al. IL⁃36γ sustains a proinflammatory self⁃amplifying loop with IL⁃17C in anti⁃TNF⁃induced psoriasiform skin lesions of patients with Crohn's disease[J]. Inflamm Bowel Dis, 2014,20(11):1891⁃1901. doi: 10.1097/MIB.0000000000000198. |
| [21] | Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan[J]. J Am Acad Dermatol, 2022,86(6):1266⁃1274. doi: 10.1016/j.jaad. 2021.06.008. |
| [22] | Torii H, Nakagawa H, Japanese Infliximab Study investigators. Long⁃term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma[J]. J Dermatol, 2011,38(4):321⁃334. doi: 10.1111/j.1346⁃8138.2010. 00971.x. |
| [23] | Morita A, Nishikawa K, Yamada F, et al. Safety, efficacy, and drug survival of the infliximab biosimilar CT⁃P13 in post⁃marketing surveillance of Japanese patients with psoriasis[J]. J Dermatol, 2022,49(10):957⁃969. doi: 10.1111/1346⁃8138.16508. |
| [24] | Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open⁃label phase 3 study[J]. J Dermatol, 2018,45(12):1371⁃1380. doi: 10.1111/1346⁃8138.14664. |
| [25] | Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phaseⅢ open⁃label multicenter Japanese study[J]. J Dermatol, 2016,43(9):1011⁃1017. doi: 10.1111/1346⁃8138.13306. |
| [26] | Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study (UNCOVER⁃J)[J]. J Dermatol, 2017,44(4):355⁃362. doi: 10.1111/1346⁃8138.13622. |
| [27] | Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study[J]. J Dermatol, 2018,45(5):529⁃539. doi: 10.1111/1346⁃8138.14294. |
| [28] | Imafuku S, Okubo Y, Tada Y, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open⁃label, phase 3 trial[J]. J Dermatol, 2024,51(3):365⁃379. doi: 10.1111/1346⁃8138.17074. |
| [29] | Rhoads J, Lavasani L, Rasouliyan L, et al. Real⁃world clinical characteristics and treatment patterns of generalized pustular psoriasis flares[J]. J Am Acad Dermatol, 2025,92(6):1243⁃1251. doi: 10.1016/j.jaad.2025.02.018. |
| [30] | Yu N, Qin H, Yu Y, et al. A distinct immature low⁃density neutrophil population characterizes acute generalized pustular psoriasis[J]. J Invest Dermatol, 2022,142(10):2831⁃2835.e5. doi: 10.1016/j.jid.2022.04.011. |
| [31] | Haskamp S, Frey B, Becker I, et al. Transcriptomes of MPO⁃deficient patients with generalized pustular psoriasis reveals expansion of CD4+ cytotoxic T Cells and an involvement of the complement system[J]. J Invest Dermatol, 2022,142(8):2149⁃2158.e10. doi: 10.1016/j.jid.2021.12.021. |
| [32] | Baldo A, Domizio JD, Yatim A, et al. Human neutrophils drive skin autoinflammation by releasing interleukin (IL)⁃26[J]. J Exp Med, 2024,221(5):e20231464. doi: 10.1084/jem.20231464. |
| [33] | Viguier M, Bentayeb M, Azzi J, et al. Generalized pustular psoriasis: a nationwide population⁃based study using the national health data system in France[J]. J Eur Acad Dermatol Venereol, 2024,38(6):1131⁃1139. doi: 10.1111/jdv.19901. |
| [34] | Lee CC, Huang YH, Chi CC, et al. Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics[J]. Trends Immunol, 2025,46(1):74⁃89. doi: 10. 1016/j.it.2024.12.001. |
| [35] | Choon SE, Lebwohl MG, Turki H, et al. Clinical characteristics and outcomes of generalized pustular psoriasis flares[J]. Dermatology, 2023,239(3):345⁃354. doi: 10.1159/000529274. |
| [36] | Xu Z, Liu Y, Zhang J, et al. Development and validation of a prognostic model for predicting flares in generalized pustular psoriasis[J]. J Eur Acad Dermatol Venereol, 2024,38(7):e599⁃e601. doi: 10.1111/jdv.19764. |
| [37] | Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis[J]. J Eur Acad Dermatol Venereol, 2017,31(11):1792⁃1799. doi: 10.1111/jdv. 14386. |
| [38] | Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP[J]. J Dermatol, 2018,45(11):1235⁃1270. doi: 10.1111/1346⁃8138.14523. |
| [39] | Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the international psoriasis council[J]. JAMA Dermatol, 2024,160(7):758⁃768. doi: 10.1001/jamadermatol. 2024.0915. |
| [40] | 《脓疱型银屑病诊疗中国专家共识(2022版)》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识(2022版)[J]. 中华皮肤科杂志, 2022,55(3):187⁃195. doi: 10.35541/cjd.20210698. |
| [41] | Choon SE, Tok P, Wong KW, et al. Clinical profile of patients with acute generalized pustular psoriasis with and without IL36RN mutations in multi⁃ethnic Johor Bahru, Malaysia[J]. Exp Dermatol, 2023,32(8):1263⁃1271. doi: 10.1111/exd.14776. |
| [42] | Farag A, Visvanathan S, Bachelez H, et al. Spesolimab reduces inflammation in generalized pustular psoriasis: molecular characterization of flare treatment in EFFISAYIL 1[J]. J Invest Dermatol, 2025,145(3):573⁃582.e8. doi: 10.1016/j.jid.2024. 05.034. |
| [1] | Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of an antioxidant gel containing tea polyphenols combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(9): 834-838. |
| [2] | Tian Cuicui, Chen Hao. Pathogenesis of cutaneous T-cell lymphoma-related pruritus [J]. Chinese Journal of Dermatology, 2025, 58(9): 890-892. |
| [3] | Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2025, 58(9): 882-885. |
| [4] | Xu Zhongyi, Xing Xiaoxue, Dong Yaqi, Zhang Chengfeng, Xiang Leihong. Retrospective analysis of clinical manifestations and treatment outcomes in 254 patients with melasma in a tertiary grade-A hospital in Shanghai [J]. Chinese Journal of Dermatology, 2025, 58(9): 808-815. |
| [5] | He Muyang, Jin Shanglin, Zhang Chengfeng. Roles of sex hormones and underlying mechanisms in the pathogenesis of melasma [J]. Chinese Journal of Dermatology, 2025, 58(9): 863-867. |
| [6] | Jiang Ziqi, Zhong Judan, Chen Tingqiao, Chen Jin. Pathogenesis and treatment of melasma [J]. Chinese Journal of Dermatology, 2025, 58(9): 868-872. |
| [7] | Zhong Jiemin, Li Wei, Zhang Shujuan, Yang Yan, Xue Rujun, Li Xinyi, Ke Yanan, Chen Xiaoyin, Chen Quan. Comparison of the efficacy and safety of nanomicroneedle- versus ultrasound-mediated delivery of tranexamic acid for the treatment of melasma: a randomized controlled study [J]. Chinese Journal of Dermatology, 2025, 58(9): 829-833. |
| [8] | Guliziba·Tuersun, Zhao Yanan, Wang Hongjuan, Kang Xiaojing, Qu Yuanyuan. Efficacy of autologous melanocyte transplantation combined with 308-nm light-emitting diode phototherapy at escalating doses in the treatment of refractory stable vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2025, 58(9): 852-856. |
| [9] | Luo Shuaihantian, Long Hai, Lu Qianjin. Research advances in systemic lupus erythematosus in 2024 [J]. Chinese Journal of Dermatology, 2025, 58(8): 777-780. |
| [10] | Bai Qi, Zhu Mingfang, Wu Qingting, Ji Xiaotian, Yang Huiyi, Ma Liping, Zhou Jiaxin. Effect of sinomenine on skin lesions in 2,4-dinitrochlorobenzene-induced atopic dermatitis-like mouse models [J]. Chinese Journal of Dermatology, 2025, 58(8): 759-766. |
| [11] | Zhan Jinshan, Xuan Xiuyun, Cao Juanmei, Chen Fangqi, Huang Changzheng. Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis [J]. Chinese Journal of Dermatology, 2025, 58(8): 785-788. |
| [12] | Zhang Li, Song Xiuzu. Role of vascular endothelial growth factor in androgenetic alopecia [J]. Chinese Journal of Dermatology, 2025, 58(7): 683-685. |
| [13] | Shao Guanghui, Li Yuqian, Chen Qitao, Zhu Qilin, Zhu Jing, Li Zhongming, Du Xufeng, Fan Weixin. Congenital triangular alopecia [J]. Chinese Journal of Dermatology, 2025, 58(7): 668-671. |
| [14] | Lin Jinran, Leong Hiochon, Liu Qingmei, Wu Wenyu. Androgenetic alopecia and metabolic syndrome: from mechanisms to treatment strategies [J]. Chinese Journal of Dermatology, 2025, 58(7): 591-594. |
| [15] | Wang Qin, Lin Jinran, Liu Qingmei, Wu Wenyu, . Oral minoxidil in the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 653-656. |
|